NO177859C - Fremgangsmåte til produksjon av angiogen faktor - Google Patents

Fremgangsmåte til produksjon av angiogen faktor

Info

Publication number: NO177859C
Authority: NO; Norway
Prior art keywords: angiogenic factor; purified; activity; disclosed; human placental
Prior art date: 1985-12-17

Application number

NO873437A

Other languages

English (en)

Other versions

NO177859B (no

NO873437L (no

NO873437D0 (no

Inventor

David A Moscatelli

Daniel B Rifkin

Andreas Sommer

Original Assignee

Synergen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-12-17

Filing date

1987-08-14

Publication date

1995-12-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO177859(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-08-14 Application filed by Synergen Inc filed Critical Synergen Inc

1987-08-14 Publication of NO873437L publication Critical patent/NO873437L/no

1987-08-14 Publication of NO873437D0 publication Critical patent/NO873437D0/no

1995-08-28 Publication of NO177859B publication Critical patent/NO177859B/no

1995-12-06 Publication of NO177859C publication Critical patent/NO177859C/no

Links

239000002870 angiogenesis inducing agent Substances 0.000 title abstract 7
238000000034 method Methods 0.000 title abstract 2
210000005059 placental tissue Anatomy 0.000 abstract 2
108091005804 Peptidases Proteins 0.000 abstract 1
239000004365 Protease Substances 0.000 abstract 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000003399 chemotactic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000002955 isolation Methods 0.000 abstract 1
230000002297 mitogenic effect Effects 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

NO873437A 1985-12-17 1987-08-14 Fremgangsmåte til produksjon av angiogen faktor NO177859C (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US80987385A	1985-12-17	1985-12-17
US88855486A	1986-07-16	1986-07-16
US89582986A	1986-08-12	1986-08-12
PCT/US1986/002669 WO1987003885A1 (en)	1985-12-17	1986-12-12	Human placenta angiogenic factor capable of stimulating capillary endothelial cell protease synthesis, dna synthesis and migration

Publications (4)

Publication Number	Publication Date
NO873437L NO873437L (no)	1987-08-14
NO873437D0 NO873437D0 (no)	1987-08-14
NO177859B NO177859B (no)	1995-08-28
NO177859C true NO177859C (no)	1995-12-06

Family

ID=27420052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO873437A NO177859C (no)	1985-12-17	1987-08-14	Fremgangsmåte til produksjon av angiogen faktor

Country Status (15)

Country	Link
EP (1)	EP0226181B1 (no)
JP (1)	JPH10262668A (no)
KR (1)	KR960015442B1 (no)
AT (1)	ATE107315T1 (no)
AU (2)	AU6774887A (no)
DE (1)	DE3689921T2 (no)
DK (1)	DK424387A (no)
ES (1)	ES2056787T3 (no)
FI (1)	FI93843C (no)
IE (1)	IE863281L (no)
IL (1)	IL80944A (no)
NO (1)	NO177859C (no)
NZ (1)	NZ218631A (no)
PT (1)	PT83939B (no)
WO (1)	WO1987003885A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5852177A (en) *	1987-02-24	1998-12-22	Takeda Chemical Industries, Ltd.	Basic fibroblast growth factor (bFGF) muteins
US4900673A (en) *	1988-03-28	1990-02-13	President And Fellows Of Harvard College	Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
WO1991006568A1 (en) *	1988-11-07	1991-05-16	Synergen, Inc.	High molecular weight human angiogenic factors
EP0580874A4 (en) *	1992-02-14	1997-02-26	Kaken Pharma Co Ltd	Remedy for airway diseases
GB9203533D0 (en) *	1992-02-19	1992-04-08	Erba Carlo Spa	Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US6749850B1 (en) *	1999-08-18	2004-06-15	The General Hospital Corporation	Methods, compositions and kits for promoting recovery from damage to the central nervous system
PT1541674E (pt)	2002-06-18	2011-03-21	Eisai R&D Man Co Ltd	Adipócitos cultivados em primário para terapia génica
CN101316602B (zh) *	2005-09-27	2015-06-03	组织技术公司	羊膜制品和纯化的组合物及其使用方法
CN111100191A (zh) *	2018-10-26	2020-05-05	神威药业集团有限公司	源于人胎盘的活性蛋白质或多肽及其用途
MX2023000267A (es) *	2020-07-16	2023-02-13	Caregen Co Ltd	Peptido con actividad neutralizante contra el coronavirus 2 del sindrome respiratorio agudo grave.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4225670A (en) *	1978-12-29	1980-09-30	Monsanto Company	Production of tumor angiogenesis factor by cell culture
US4209587A (en) *	1978-12-29	1980-06-24	Monsanto Company	Production of tumor angiogenesis factor by cell culture
DE3110560A1 (de) *	1981-03-18	1982-10-14	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen	"angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
US4529590A (en) *	1982-12-27	1985-07-16	Leveen Robert F	Production of angiogenetic factor
GB2146523B (en) *	1983-09-13	1987-01-07	Ward Page Faulk	Preparation for stimulating growth of blood vessels prepared from amniochorionic tissue and macrophages
EP0248819B2 (en) *	1985-09-12	2000-08-30	Scios Inc.	Recombinant fibroblast growth factors
IL81650A0 (en) *	1986-02-24	1987-09-16	Robapharm Ag	Purified human angiogenic factor,method for its preparation and pharmaceutical preparations

1986
- 1986-12-11 IL IL8094486A patent/IL80944A/en not_active IP Right Cessation
- 1986-12-11 AT AT86117257T patent/ATE107315T1/de not_active IP Right Cessation
- 1986-12-11 DE DE3689921T patent/DE3689921T2/de not_active Expired - Fee Related
- 1986-12-11 EP EP86117257A patent/EP0226181B1/en not_active Revoked
- 1986-12-11 ES ES86117257T patent/ES2056787T3/es not_active Expired - Lifetime
- 1986-12-12 WO PCT/US1986/002669 patent/WO1987003885A1/en not_active Ceased
- 1986-12-12 KR KR1019870700727A patent/KR960015442B1/ko not_active Expired - Fee Related
- 1986-12-12 AU AU67748/87A patent/AU6774887A/en not_active Abandoned
- 1986-12-15 NZ NZ218631A patent/NZ218631A/en unknown
- 1986-12-16 PT PT83939A patent/PT83939B/pt not_active IP Right Cessation
- 1986-12-16 IE IE863281A patent/IE863281L/xx not_active Application Discontinuation
1987
- 1987-08-14 NO NO873437A patent/NO177859C/no unknown
- 1987-08-14 DK DK424387A patent/DK424387A/da not_active Application Discontinuation
1988
- 1988-06-16 FI FI882891A patent/FI93843C/fi not_active IP Right Cessation
1991
- 1991-04-29 AU AU76299/91A patent/AU650649B2/en not_active Ceased
1998
- 1998-01-28 JP JP10015790A patent/JPH10262668A/ja active Pending

Also Published As

Publication number	Publication date
PT83939A (en)	1987-01-01
FI882891A0 (fi)	1988-06-16
NO177859B (no)	1995-08-28
AU650649B2 (en)	1994-06-30
AU6774887A (en)	1987-07-15
IL80944A (en)	1994-10-07
EP0226181A2 (en)	1987-06-24
FI93843C (fi)	1995-06-12
KR880700820A (ko)	1988-04-12
IL80944A0 (en)	1987-03-31
EP0226181B1 (en)	1994-06-15
JPH10262668A (ja)	1998-10-06
ATE107315T1 (de)	1994-07-15
KR960015442B1 (ko)	1996-11-14
IE863281L (en)	1987-06-17
AU7629991A (en)	1991-08-08
EP0226181A3 (en)	1989-03-08
WO1987003885A1 (en)	1987-07-02
DK424387D0 (da)	1987-08-14
DE3689921T2 (de)	1994-09-22
DE3689921D1 (de)	1994-07-21
FI882891L (fi)	1988-06-16
PT83939B (pt)	1989-05-31
NO873437L (no)	1987-08-14
NZ218631A (en)	1991-07-26
ES2056787T3 (es)	1994-10-16
FI93843B (fi)	1995-02-28
DK424387A (da)	1987-08-14
NO873437D0 (no)	1987-08-14

Publication	Publication Date	Title
DK601786A (da)	1986-12-12	Hidtil ukendte prokoagulationsproteiner
DK0751992T3 (da)	2006-03-06	Karendotelvækstfaktor 2
NO177678C (no)	1995-11-01	Fremgangsmåte for fremstilling av et terapeutisk aktivt, rekombinant protein som har ASP-aktivitet, ekspresjonssystem samt DNA som koder for nevnte protein
FI102379B1 (fi)	1998-11-30	Uretaanisuojattuja aminohappo-N-karboksianhydridejä
ATE205254T1 (de)	2001-09-15	Transformierender wachstumsfaktor alpha h1
NO871574D0 (no)	1987-04-14	Fremgangsmaate for fremstilling av terapeutisk aktive peptider.
CA2062969A1 (en)	1991-01-22	Recombinantly produced human membrane cofactor protein (mcp)
NO871295D0 (no)	1987-03-27	Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
EP0218531A3 (en)	1989-07-12	Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
FI882891A0 (fi)	1988-06-16	Menetelmä angiogeenisen tekijän tuottamiseksi
DE3685651D1 (de)	1992-07-16	Den antigenischen und immunogenischen determinanten von wichtigen neutralisierenden proteinen des rotavirus entsprechende peptide.
DE3777845D1 (de)	1992-05-07	Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
NO870049D0 (no)	1987-01-06	Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO863373D0 (no)	1986-08-21	Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyre derivater.
DK288789D0 (da)	1989-06-13	Peptider og syreadditionssalte deraf, deres fremstilling og anvendelse
DK229387A (da)	1987-11-07	Retinoesyreestere, deres fremstilling og farmaceutiske og kosmetiske praeparater deraf
EP0183506A3 (en)	1988-11-02	Use of thioredoxin and other dithiol peptides in hair care
IT1217314B (it)	1990-03-22	Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
EP0272894A3 (en)	1989-06-14	Recombinant human lymphotoxin
PT85226A (en)	1987-08-01	Process for the preparation of novel trombolytic proteins